Page 71 - วารสารการแพทย์แผนไทยและการแพทย์ ทางเลือก ปีที่ 19 ฉบับที่ 2 พฤษภาคม-สิงหาคม 2564

J Thai Trad Alt Med Vol. 19 No. 2 May-Aug 2021 301

plasma concentrations of Baloxavir Marboxil and favipi- Kitamura H, Baba T, Komatsu S, Iwasawa T, Kaneko, T,
ravir in COVID-19 patients: An exploratory randomized, Ogura T. Outcome of early-stage combination treatment
controlled trial. Eur. J. Pharmaceut.Sci. 2020;157:105631 with favipiravir and methylprednisolone for severe CO-
40. Udwadia ZF, Singh P, Barkate H, Patil S, Rangwala S, VID-19 pneumonia: A report of 11 cases. Respir Investig.
Pendse A, Kadam J, Wu W, Caracta CF, Tandon M. Ef- 2020;S2212–5345(20):30117–9.
ficacy and safety of favipiravir, an oral RNA-dependent 49. Başaran NC, Uyaroğlu OA, Telli Dizman G, Özişik L,
RNA polymerase inhibitor, in mild-to-moderate şahin TK, Taş Z, İnkaya AC, Sarahan S, Alp S, Apl
COVID-19: A randomized, comparative, open-label, A, Metan G, Zarakol P, Guven GS, Oz SG, Topeli A,
multicenter, phase 3 clinical trial. Int. J. Infect. Dis. Uzun O, Akova M, Unal S. Outcome of non-critical
2020;103:62-71 COVID-19 patients with early hospitalization and early
41. Zhao H, Zhu Q, Zhang C, Li J, Wei M, Qin Y, Chen G, antiviral treatment outside the ICU. Turk J Med Sci.
Wang K, Yu J, Wu Z, Chen X, Wang G. Tocilizumab 2021;51(2):411-20
combined with favipiravir in the treatment of COVID-19: 50. Yaylaci S, Dheir H, Şenocak D, Genc AB, Kocayigit H,
A multi center trial in a small sample size. Biomed. Çekiç D, Varim C, Aydin A, Koroglu M, Karabay O. The
Pharmacother. 2021;133 effects of favipiravir on hematological parameters of
42. Manabe T, Kambaysshi D, Akatsu H, Kudo K. favipi- covıd-19 patients. Rev Assoc Med Bras. 2020;66 Suppl
ravir for the treatment of patients with COVID-19: a 2(Suppl 2):65–70.
systematic review and meta-analysis. BMC infect Dis 51. Cáceres DD, Hancke JL, Burgos RA, Sandberg F, Wik-
2021;21:489 man GK. Use of visual analogue scale measurements
43. Hassanipour S, Arab-Zozani M, Amani B, Heidarzad (VAS) to assess the effectiveness of standardized
F, Fathalipour M, Martinez-de-Hoyo R. The efficacy Andrographis paniculata extract SHA-10 in reducing
and safety of favipiravir in treatment of COVID-19: a the symptoms of common cold. A randomized double
systematic review and meta-analysis of clinical trials. blind-placebo study. Phytomed. 1999;6(4):217-23.
Sci Rep. 2021;11:11022. 52. Hancke J, Burgos R, Caceres D, Wikman GK. A double-
44. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu blind study with a new monodrug Kan Jang: decrease
Y, Cai Q, Yang Y, Shen C, Li X, Peng L, Huang D, Zhang of symptoms and improvement in the recovery from
J, Zhang S, Wang F, Liu J, Chen L, Chen S, Wang Z, common colds. Phytothe Res 1995;9:559-62.
Zhang Z, Cao R, Zhong W, Liu Y, Liu L. Experimental 53. Malchior J, Palm S, Wikman GK. Controlled clinical
treatment with favipiravir for COVID-19: an open-label study of standardized Andrographis paniculata extract
control study. Engineering. 2020;6(10):1192-8 in common cold – a pilot trial. Phytomed. 1997;3(4):315-8.
45. Doi K, Ikeda M, Hayase N, Moriya K, Morimura N, CO- 54. Thamilikitkul V, Dechatiwongse T, Theerapong S,
VID-UTH Study Group. Nafamostat mesylate treatment Chantrakul C, Boonroj P, Punkrut W, Espalakorn W,
in combination with favipiravir for patients critically ill Boontaeng N, Taechaiya S, Petcharoen S. Efficacy of
with Covid-19: a case series. Crit Care. 2020;24(1):392. Andrographis paniculata, Nees for pharyngotonsillitis
46. Yamamura H, Matsuura H, Nakagawa J, Fukuoka in adults. J Med Assoc Thailand. 1991;74(10)437-42.
H, Domi H, Chujoh S. Effect of favipiravir and an 55. Malchior J, Spassov AA, Ostrovskij OV, Bulanov AE,
anti-inflammatory strategy for COVID-19. Crit Care. Wikman GK. Double-blind, placebo-controlled pilot and
2020;413(1):413. phase III study of activity of standardized Andrographis
47. Rattanaumpawan P, Jirajariyavej S, Lerdlamyong K, paniculata herba Nees extract fixed combination (Kan
Palavutitotai N, Saiyarin J. Real-world experience with Jang) in the treatment of uncomplicated upper-respira-
favipiravir for treatment of COVID-19 in Thailand: Re- tory tract infection. Phytomed. 2000;7(5):341-5.
sults from a multi-center observational study. medRxiv. 56. Saxena RC, Singh R, Kumar P, Yadav SC, Negi MPS,
doi: 10.1101/2020.06.24.20133249. Saxena VS, Joshua AJ, Vijayabalaji V, Goudar KS,
48. Murohashi K, Hagiwara E, Kitayama T, Yamaya T, Higa Venkateshwarlu K, Amit A. A randomized double
K, Sato Y, Otoshi R, Shintani R, Okabayashi H, Ikeda blind placebo controlled clinical evaluation of extract
S, Niwa T, Nakazawa A, Oda T, Okuda R, Sekine A, of Andrographis paniculata (KalmCold) in patients